Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics · Glycogen Storage Disease Type I

Assembling Your GSD Care Team

At a Glance

Managing GSD 1 requires a specialized care team led by a metabolic geneticist and dietitian. In emergencies where oral cornstarch cannot be taken, patients need immediate IV dextrose. Emergency staff must avoid using Glucagon or Lactated Ringer's, as these can trigger lethal lactic acidosis.

Managing Glycogen Storage Disease Type I (GSD I) is a “team sport.” Because the condition affects multiple systems in the body—including metabolism, the liver, the kidneys, and (in the case of GSD Ib) the immune system—you will need a group of specialists who work together to provide comprehensive care [1].

Your Care Team Roster

A high-quality metabolic center should provide access to the following experts:

  • Metabolic Geneticist: This is usually the “quarterback” of the team. They specialize in inherited disorders and oversee the overall treatment plan and genetic confirmations [2].
  • Metabolic Dietitian: Perhaps the most important daily contact for a GSD family. They calculate the precise cornstarch doses and feeding schedules needed to maintain stability [3][4].
  • Hepatologist (Liver Specialist): Because GSD I causes the liver to enlarge and carries a risk of liver tumors (adenomas), a hepatologist will perform regular imaging and monitor liver health [5][6].
  • Nephrologist (Kidney Specialist): Long-term GSD management involves protecting the kidneys from the effects of chronic metabolic stress [7].
  • Endocrinologist: They may assist with growth monitoring and hormone balance, as GSD I can impact height and development [8].
  • Specialists for GSD Ib: If your child has Type Ib, you will also need an Immunologist to manage white blood cell issues (neutropenia) and a Gastroenterologist to monitor for inflammatory bowel disease (IBD) [9][10].

Evaluating a Metabolic Center

Not all hospitals are equipped to handle GSD I. When choosing where your child will receive care, consider these three “vetting” criteria:

  1. Volume of Patients: Ask how many GSD I patients they currently treat. Experience matters in rare diseases [11].
  2. Access to Technology: Ensure the center is proactive in using tools like Continuous Glucose Monitors (CGM) and analyzing the data to refine the treatment plan [12][13].
  3. Emergency Support: Confirm they have a clear, established system for handling after-hours emergencies [14].

The Emergency Protocol

In GSD I, an emergency is defined as any time a patient cannot take their cornstarch or feedings orally (such as during vomiting, a stomach flu, or before surgery) [11]. Without an external source of glucose, blood sugar can drop to dangerous levels within hours, leading to lactic acidosis [15][1].

The Emergency Letter
Your metabolic team must provide you with a signed Emergency Protocol Letter. You should present this immediately upon arriving at any Emergency Room. This letter is critical because it instructs ER staff to bypass “standard” procedures and start life-saving treatment [16]. Your letter MUST include:

  • Immediate IV Access: The patient needs an intravenous (IV) line right away [14].
  • Continuous Dextrose: They must receive a continuous infusion of glucose-containing fluids (often D10, or 10% dextrose) to keep blood sugar stable [14][17].
  • Glucose Infusion Rate (GIR): The letter should specify the exact “Glucose Infusion Rate” needed based on weight to prevent metabolic collapse [14].

CRITICAL WARNINGS FOR EMERGENCY STAFF:
Standard emergency treatments for low blood sugar or dehydration can be lethal for a GSD I patient. Your Emergency Letter must explicitly instruct staff to AVOID:

  1. Glucagon: Paramedics and ERs often use a Glucagon shot to treat severe hypoglycemia. In GSD I, the liver is physically incapable of responding to Glucagon. It will not raise blood sugar, but it will cause a massive, dangerous spike in lactic acid [18].
  2. Lactated Ringer’s Solution: ERs frequently use this common IV fluid for dehydration. Because it contains lactate, giving it to a GSD I patient will severely worsen their existing lactic acidosis [15].

Common questions in this guide

Which doctors should be on a GSD 1 care team?
A comprehensive care team should be led by a metabolic geneticist and a metabolic dietitian. Because the disease affects multiple systems, you will also need a hepatologist for the liver, a nephrologist for the kidneys, and an endocrinologist for growth and hormones.
What information must be included in a GSD emergency letter?
The letter must explicitly direct emergency room staff to start immediate IV access with continuous dextrose, typically 10% dextrose (D10). It must also specify the patient's exact glucose infusion rate based on their weight to prevent a metabolic crash.
Why is Glucagon dangerous for patients with GSD 1?
In GSD 1, the liver is physically unable to respond to Glucagon injections. Instead of raising blood sugar, Glucagon causes a massive, dangerous spike in lactic acid that can be life-threatening.
How do I know if a metabolic center is equipped to handle GSD?
Look for a center that treats a high volume of GSD patients, as experience is critical with rare diseases. Additionally, ensure they proactively use continuous glucose monitors (CGMs) and have an established protocol for supporting local emergency rooms after hours.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with GSD I (specifically our child's subtype) does your clinic currently manage?
  2. 2.Does your center provide a 24/7 on-call service with a metabolic specialist who can guide ER doctors during an emergency?
  3. 3.Can you provide us with a signed 'Emergency Letter' that specifies our child's diagnosis, exact IV glucose requirements, and contraindications?
  4. 4.How do the different specialists on our team (dietitian, geneticist, hepatologist) communicate with each other to coordinate care?
  5. 5.What is your center's experience with newer treatments like Empagliflozin for GSD Ib or Continuous Glucose Monitoring (CGM) optimization?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Glucose-6 Phosphate, A Central Hub for Liver Carbohydrate Metabolism.

    Rajas F, Gautier-Stein A, Mithieux G

    Metabolites 2019; (9(12)) doi:10.3390/metabo9120282.

    PMID: 31756997
  2. 2

    The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy.

    Tan LS, Lau HH, Abdelalim EM, et al.

    Trends in molecular medicine 2025; (31(2)):152-164 doi:10.1016/j.molmed.2024.09.005.

    PMID: 39426930
  3. 3

    Investigation and management of the hepatic glycogen storage diseases.

    Bhattacharya K

    Translational pediatrics 2015; (4(3)):240-8 doi:10.3978/j.issn.2224-4336.2015.04.07.

    PMID: 26835382
  4. 4

    Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.

    Ross KM, Brown LM, Corrado MM, et al.

    JIMD reports 2016; (26()):85-90 doi:10.1007/8904_2015_488.

    PMID: 26303612
  5. 5

    [Advances on the management of renal lesion in glycogen storage disease type I].

    Wu WC, Wang JS

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021; (29(1)):75-78 doi:10.3760/cma.j.cn501113-20201230-00687.

    PMID: 33541027
  6. 6

    Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study.

    Jang HJ, Yang HR, Ko JS, et al.

    Journal of Korean medical science 2020; (35(1)):e5 doi:10.3346/jkms.2020.35.e5.

    PMID: 31898434
  7. 7

    Kidney involvement in glycogen storage disease type I: Current knowledge and key challenges.

    Schumann A, Garbade SF, Beblo S, et al.

    Molecular genetics and metabolism 2025; (144(3)):109054 doi:10.1016/j.ymgme.2025.109054.

    PMID: 39954548
  8. 8

    Hepatic Glycogenosis In Children: Spectrum Of Presentation And Diagnostic Modalities.

    Bilal H, Cheema HA, Fayyaz Z, et al.

    Journal of Ayub Medical College, Abbottabad : JAMC 2019; (31(3)):368-371.

    PMID: 31535508
  9. 9

    A novel SLC37A4 missense mutation in GSD-Ib without hepatomegaly causes enhanced leukocytes endoplasmic reticulum stress and apoptosis.

    Xu Q, Tang H, Duan L, et al.

    Molecular genetics & genomic medicine 2021; (9(1)):e1568 doi:10.1002/mgg3.1568.

    PMID: 33280276
  10. 10

    Gastrointestinal complications of hepatic glycogen storage disease: a national survey questionnaire study in China.

    Zhang X, Su Z, Wu J, et al.

    Orphanet journal of rare diseases 2025; (20(1)):41 doi:10.1186/s13023-025-03570-1.

    PMID: 39875987
  11. 11

    Impact of glycogen storage disease type I on adult daily life: a survey.

    Garbade SF, Ederer V, Burgard P, et al.

    Orphanet journal of rare diseases 2021; (16(1)):371 doi:10.1186/s13023-021-02006-w.

    PMID: 34479584
  12. 12

    Hypoglycaemic Unawareness in a Glycogen Storage Disorder Patient: A Case Report and Review of the Literature.

    Alkundi A, Momoh R

    Cureus 2025; (17(4)):e81805 doi:10.7759/cureus.81805.

    PMID: 40330337
  13. 13

    Role of continuous glucose monitoring in the management of glycogen storage disorders.

    Herbert M, Pendyal S, Rairikar M, et al.

    Journal of inherited metabolic disease 2018; (41(6)):917-927 doi:10.1007/s10545-018-0200-5.

    PMID: 29802555
  14. 14

    Patients with glycogen storage diseases undergoing anesthesia: a case series.

    Gurrieri C, Sprung J, Weingarten TN, Warner ME

    BMC anesthesiology 2017; (17(1)):134 doi:10.1186/s12871-017-0428-x.

    PMID: 28985713
  15. 15

    Recoverable, Record-High Lactic Acidosis in a Patient with Glycogen Storage Disease Type 1: A Mixed Type A and Type B Lactate Disorder.

    Oster Y, Wexler ID, Heyman SN, Fried E

    Case reports in medicine 2016; (2016()):4362743 doi:10.1155/2016/4362743.

    PMID: 27974893
  16. 16

    Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review.

    Rossi A, Rutten MGS, van Dijk TH, et al.

    Frontiers in endocrinology 2022; (13()):858832 doi:10.3389/fendo.2022.858832.

    PMID: 35789807
  17. 17

    Anesthetic management for dental surgery in a child with glycogen storage disease type IIIa: a case report.

    Aykenar B, Çekmen N

    Journal of dental anesthesia and pain medicine 2022; (22(6)):451-455 doi:10.17245/jdapm.2022.22.6.451.

    PMID: 36601131
  18. 18

    Fluorodeoxyglucose-positron emission tomography as a potential alternative tool for functional diagnosis of glycogen storage disease type I.

    Sato T, Inokuchi M, Nakano S, et al.

    Radiology case reports 2023; (18(1)):91-93 doi:10.1016/j.radcr.2022.09.084.

    PMID: 36324837

This page explains care team structures and emergency protocols for Glycogen Storage Disease Type 1 for educational purposes only. Always rely on your metabolic specialist for daily care and present your official Emergency Protocol Letter to medical staff during emergencies.

Get notified when new evidence is published on Glycogen storage disease due to glucose-6-phosphatase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.